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Abstract
Few studies on the humoral immune responses in human during natural influenza infection have been reported. Here, we
used serum samples from pandemic 2009 H1N1 influenza infected patients to characterize the humoral immune responses
to influenza during natural infection in humans. We observed for the first time that the pandemic 2009 H1N1 influenza
induced influenza A-specific IgM within days after symptoms onset, whereas the unit of IgG did not changed. The
magnitude of influenza A-specific IgM antibodies might have a value in predicting the rate of virus clearance to some
degree. However, the newly developed IgM was not associated with hemagglutination inhibition (HI) activities in the same
samples but correlated with HI activities of subsequently collected sera which were mediated by IgG antibodies, indicating
that IgM was critical for influenza infection and influences subsequent IgG antibody responses. These findings provide new
important insights on the human immunity to natural influenza infection.
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Introduction
Adaptive humoral immunity is an essential component of immune
responses to different microbe infections including influenza. Different
isotypes of immunoglobulin (Ig) constitute the adaptive humoral
immunity to influenza and play different roles in protection and
pathogenesis [1]. Influenza specific IgG is superior to other isotypes in
neutralization activity and is able to effectively contain progeny virus
when used as a regiment of immunotherapy in immunodeficient mice
[2]. Secreted IgM in acute phase of infection also plays important role
in protection from influenza virus. Both natural IgM produced by B-1
cells in the absence of exposure to virus and antigen induced IgM
secreted by B-2 cells after antigen stimulation nonredundantly
contribute to immune protection from infection of influenza virus
[3]. However, most of these data have been collected from mice
infection model. Infection of Influenza usually lasts for a week and most
infected people with mild symptoms recover within weeks without
hospitalization, which renders it difficult to collect samples during the
early acute infection from clinical settings. So far no observation
intensively monitoring early humoral responses to the pandemic or
seasonal influenza infection in humans has been reported.
On April 15 and 17, 2009, two epidemiologically unlinked
cases of new swine influenza A in children residing in California
were reported [4]. Sequence analysis revealed that genetic
characterization of the virus was a combination of gene
segments derived from triple reassortant North American and
Eurasian swine lineages [5,6,7,8,9]. Within weeks this novel
strain of influenza spread globally by human-to-human
transmission [10]. The outbreak of influenza infection had
received much attention from public than ever before in last
decades and many strategies had been employed to prevent its
spread. On May 24, 2009, we identified a Chinese working in
Australia as the first case of 2009 pandemic H1N1 infection in
Shanghai, which marked the beginning of sporadic 2009 H1N1
cases in east China. To prevent community epidemic, all
patients indentified from May 24
th to July 9
th in Shanghai were
quarantined and treated in Shanghai Public Health Clinical
Center until the viral loads of their nasopharyngeal swab
became undetectable. This opportunity allowed us to collect
sera of influenza infected patients longitudinally and initiated
experiments aiming at characterizing early humoral immune
responses to influenza.
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Patients and Serum samples
131 patients hospitalized in Shanghai Public health Clinical
Center (SHAPHC) received diagnostic of 2009 H1N1 infection,
which had been confirmed by mean of real time PCR.
Nasopharyngeal swab was obtained daily for monitoring the
change of the concentration of viral genome, in terms of viral load.
Among these H1N1 patients, 73 subjects had serum samples on
two or more days. The majority of these patients (99.6%) received
oseltamivir according to H1N1 treatment protocol and had been
stayed in hospital for 3–9 days. A set of outpatient sera was
gathered for non-influenza serological testing in September of
2008 as non-exposed control. Sera of Human respiratory syncytial
virus, parainfluenza and adenovirus infected subjects were
collected from laboratories participating regional respiratory
disease surveillance program. Sera of HIV cohort were obtained
in September of 2009 and in June of 2010.
Ethics Statement
Written informed consents were obtained from all 2009
Influenza A (H1N1) infected subjects right after they were
admitted into hospital and from all participants in HIV cohorts.
Storage sera collected from outpatients in 2008 during non-flu
season and sera of human respiratory syncytial virus, parainflu-
enza and adenovirus infected subjects were fully delinked from
patient personal information by the removal of all labels from
samples before they were tested per the requirement from Ethics
Committee of SHAPHC. The overall study was reviewed and
proved by the Ethics Committee of SHAPHC.
Measurement of anti-influenza A antibodies by ELISA
Commercial ELISA kits were used to assess the units of IgG
(Minneapolis, Minnesota, IBL, Cat# IB79251) and IgM (Minne-
apolis, Minnesota, IBL, Cat# IB79252) antibodies to influenza A
following manufacture’s instruction. Briefly, 100 mL each of the
1:100 diluted samples and the standards were added respectively
into the wells and incubated at room temperature for 60 minutes.
After three washes with washing solution, the wells were incubated
with peroxide-conjugated anti-human IgG or anti-human IgM
antibodies at room temperature for 30 minutes. Plates were then
washed for another three times and 100 mL TMB substrate was
pipetted and incubated at room temperature for approximately
20 minutes. After development of a blue dye in the wells, reaction
was terminated by the addition of 100 mL stop solution. In IgM
ELISA, to eliminate interference from hyper-immune levels of IgG
or rheumatoid factors, sera were pretreated with RF adsorbent
(Minneapolis, Minnesota, IBL, Cat# 79000) according to
manufacture’s instruction. Samples with unit of IgM $12 were
considered positive as suggested by manufacture’s instruction.
Hemagglutination-inhibition (HAI) assays
Serum sample were treated with receptor destroying enzyme
(RDE) (St. Louis, MO, Sigma, Cat# C8772) to inactivate non-
specific inhibitors. Then serially diluted 2-fold into U-bottom 96-
well microtiter plates starting at a dilution of 1:10 and stopping at
1:320 in volume of 50 mL. 50 mL of virus adjusted to approxi-
mately 8 HA units was added. The plates were covered and
incubated at room temperature for 30 min followed by the
addition of 1% gninea pig erythrocytes (RBCs) in PBS. The plates
were mixed by agitation, covered, and allowed to set for 60 min at
room temperature. The HI titer was determined by the reciprocal
of the last dilution that contained non-agglutinated RBCs. 2009
H1N1 vaccinated serum was used as positive control and serum
from naı ¨ve mouse raised under specific pathogen free circumven-
tions was used as negative serum controls. Samples with HI titers
$1:40 were considered seropositive. The virus strain used was A/
Shanghai/37T/2009(H1N1) (SH37T) (Genebank ID: AC-
S27776,ACS27785), which shares 99.47% similarity of HA
protein sequence (M8L, S220T, V428C) to A/California/04/
2009.
Removal of IgM and IgG
Five serum samples with both high unit of IgM and high titer of
HI were pooled. IgG was removed using Protein G - sepharose
beads. Briefly, 200 mL of Protein G –sepharose beads was washed
for three times with ice cooled PBS. At the final wash, the
supernatant was aspired after centrifuging and 100 mL of pooled
serum was added. Incubated the serum-beads mixture at 4uC
under rotary agitation for 1 hour, centrifuged the tube and keep
the supernatant as IgG depleted serum. All steps were repeated for
three times to remove abundant IgG. In the case of IgM depletion,
instead of Protein G - sepharose beads, anti-human IgM antibody
was incubated with Protein G - sepharose beads prior to addition
of pooled serum.
Statistics analysis
Geometric mean titers (GMTs) were calculated by assigning a
titer of 5 to samples no HI antibody was detected at the starting
dilution (titer,10). Mann-Whitney U test was used to calculate p-
value when compared GMT between two groups. Wilcoxon
signed rank test was used to calculate p-value when compared
GMT between paired data. Spearman’s rank correlation coeffi-
cient was used to calculate the correlation between the unit of IgM
and the titer of HI. Log-rank (Mantel-Cox) test was used to
compare survival curves and to calculated hazard ratio and its
95% confidence intervals (CI) of the association of factors. Chi-
square test was used to calculate p value, odds ratios (OR) and
95% confidence intervals (CI) of the association of factors in




1. Early IgM responses in individuals recently infected
with pandemic H1N1 influenza viruses
As the first immunoglobulin class produced during microbial
infection, IgM is widely accepted as the first line of primary
immune response and diminishes quickly in few days of infection.
Firstly we examine whether the influenza A-specific IgM in sera
could reflect the history of recent exposure to influenza A.
Influenza A-specific IgM and IgG were quantified in samples of
131 pandemic 2009 H1N1 infected patients on the 1
st or 2
nd day
after they were admitted into hospital. As showed in figure 1a,
among 131 samples of 2009 H1N1 infected patients who were
finally confirmed by real time PCR, 111 (84.7%) samples were
positive for anti-influenza A IgM, whereas only 6 (6%) out of 100
serum samples colleted in September of 2008 that was not a flu
pandemic season were positive (OR=86.95, 95%CI [34.10–
220.39], p,0.0001). These data gave rise to the sensitivity at
94.9% with 95%CI from 89.2% to 98.1% and the specificity at
82.5% with 95%CI from 74.2% to 88.9%. To further determine
the specificity of the IgM assay, a panel of serum samples from
other acute respiratory viral infections including RSV, parainflu-
enza and adenovirus were also tested and all of them were negative
for influenza A-specific IgM. Besides those samples, we used
residual serum samples taken from a HIV cohort study to validate
whether Influenza A-specific IgM is a surrogate marker for recent
Antibodies in Human Natural Influenza Infection
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colleted in the epidemic wave of 2009 H1N1 influenza (Sep. 2009)
were positive for influenza A-specific IgM, whereas none was
positive in samples collected in June of 2010. In contrast to IgM,
high influenza A -specific IgG level was detected in almost all
individuals (Fig. 1b), indicating that almost all individuals were
infected by influenza A or were vaccinated with seasonal flu
vaccine before.
We next examined whether the development of IgM antibodies
was associated with patient gender, viral loads, genetic background
and ages (Fig. 2). The unit of IgM was not significantly associated
with sex (Mann-Whitney U test, p=0.235) (Fig. 2a). Spearman’s
rank correlation coefficient between the unit of IgM and viral load
of nasopharyngeal swab was 0.072, suggesting no correlation
(p=0.458) (Fig. 2b). There was no significant difference of the unit
of IgM when samples were grouped by nationality (Kruskal-Wallis
test, p=0.720) (Fig. 2c). Slight higher unit of IgM was observed in
age group of 5–10 years than others, but it did not reach statistic
significance due to few child cases (28.36 VS 18.73, p=0.107)
(Fig. 2d). The longitudinal kinetic of IgM in population was also
examined. The percentage of positive IgM was slightly increased
from 84.9% on the 2
nd and 3
th day of symptom onset to 92.7% on
the 4–10
th day of symptom onset and the geometric mean
increased from 18.92 to 21.93 (p=0.012) (Fig. 3).
Overall, our data suggested that anti-influenza A IgM could be
newly developed within days after exposure to 2009 H1N1
influenza. Patient gender, viral loads, genetic background and ages
have no significantly role in the development of anti-influenza A
IgM antibodies.
2. IgM plays a minor role in virus clearance
Since secreted IgM is an important component in protective
responses to influenza in mouse model, we performed an analysis
to understand whether IgM level was correlated with virus
clearance at this early course of human natural infection. The
outcome event was defined as viral load of nasopharyngeal swab
became undetectable. The patients were divided into quartiles
according to either the unit of IgM or viral loads on the 2
nd day of
symptom onset. As showed in Fig. 4a, the group with highest
copies of viral load had been stayed in hospital for a median of 5
days and the ones with lowest viral loads for 3 days (hazard
ratio=8.665, 95%CI [3.948–19.02], p,0.0001), the 2
nd and 3
rd
quartiles of initial viral loads intercalated between the 1
st and 4
th
quartiles (Figure S1a), suggesting the initial viral loads in
nasopharynx is prognostic marker for virus clearance. We then
tested whether the IgM is a prognostic marker for virus clearance.
Interestingly, the group with highest units of IgM cleared the virus
fairly quicker than the ones with lowest units (hazard ratio=0.582,
95%CI [0.296–0.835], p=0.041) (Fig. 4b), despite viral loads were
comparable between these two groups (Fig. 4c). This was much
manifested between day 3 and 5 after admission. However, given
the comparison was performed between the highest and lowest
IgM groups and the difference was relatively minor, we concluded
that IgM may only play a minor role in viral clearance during
human influenza infection, this was also evidenced in the groups
with modest units of IgM (the 2
nd and 3
rd quartiles of IgM units) in
which only minor differences were observed in their clearance
days from those two extreme groups (Figure S1b).
3. Hemagglutination-inhibition activities in individuals
recently infected with pandemic H1N1 influenza viruses
To understand whether IgM was correlated with hemaggluti-
nation-inhibition (HI) activities at this early course of infection, we
performed HI assay. The virus strain used was SH37T, a primary
virus isolated from a 30 years old male patient in our own
laboratory. As shown in Fig. 5a (left), 7 out 131 sera on the 2
nd day
of symptom onset reached HI titers $40 and 2 of them even
reached titers at 80 whereas the majority had undetectable HI
activities which was lower than 10. In week of symptom onset, the
HI activity continuously elevated and most increased to titer at 10
or 20, a fraction of them reached titer .40, which was particularly
on 5 days after admission (Fig. 5a). Since some of patients were
released before the collection of their second samples during day
4–10, in order to exclude the bias resulted from unbalanced
Figure 1. Influenza A specific IgM and IgG in serum samples from 2009 pandemic H1N1 infected patients and non-influenza related
sources. The units of IgM (a) and IgG (b) antibodies to influenza A in sera were determined by commercial ELISA kits. 131 pandemic 2009 H1N1
influenza infected samples, 100 samples collected in Sep. 2008, 3 acute RSV infected samples, 8 acute parainfluenza infected samples, 11 acute
adenovirus infected samples and samples from 60 HIV+ subjects taken in Sep. 2009 and Jun. 2010 were also used in this experiment. In the box plot,
the whiskers represent 10–90th percentile.
doi:10.1371/journal.pone.0022603.g001
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U test was used to test the difference of IgM between 58 female and 71 male H1N1 infected patients; b) The association between 109 paired data of
IgM and viral loads in nasopharyngeal swab was analyzed using spearman rank correlation; c) The difference of grouped samples by nationality was
tested by Kruskal-Wallis test; d) Age distribution of IgM. All data were derived from samples of the 2nd day post symptom onset.
doi:10.1371/journal.pone.0022603.g002
Figure 3. Time course of IgM in week of H1N1 infection. a) IgM grouped by days since of illness; b) Longitudinal kinetic of IgM in 73 paired
subjects who had seral samples with multiple time-points.
doi:10.1371/journal.pone.0022603.g003
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from 73 subjects, including one was collected within 3 days after
illness onset and the other was collected during day 4–10 from
each subject, and demonstrated that HI titers in samples collected
during day 4–10 were significantly higher than those in samples
collected within 3 days (Fig. 5b). The HI activities against seasonal
H3 were not changed, suggesting no cross-reaction relationship
between 2009 pandemic H1N1 and seasonal H3 for their HI
activities (Fig. 5c).
Interestingly, the unit of IgM in serum collected at admission
was not significantly associated with HI titer in the same samples
(Spearman’s rank correlation rho=0.117, p=0.326, Fig. 6a) but
correlated with HI titer of serum samples colleted before discharge
(Spearman’s rank correlation rho=0.299, p=0.010, Fig. 6b).
Interestingly, HI titers of sera from patients who cleared the virus
was higher than that in non-cleared subjects though statistical
significance was not reached (Figure S2).To test the how much the
different subtypes of immunoglobulins contribute to HI activities,
IgM and IgG in pooled sera were removed respectively. When
IgM was depleted from the sera, the HI activities still remained
(Fig. 6c). In contrast, the removal of IgG resulted in a significant
decline of HI activities (Fig. 6d).
These data suggest that early developed influenza A-specific
IgM antibodies are unable to exert HI activities but associated
with the subsequent development of influenza A-specific IgG
antibodies which could exert HI activities and might be associated
with viral clearance; Good influenza A-specific IgM responses at
very early phase could be considered as a marker of better
influenza A-specific immune response in host and thereby
associated with the early virus clearance.
Discussion
The pandemic of 2009 H1N1 influenza infection has posed a
challenge to global public health and emphasized the importance
to conduct influenza surveillance in general population. A
biomarker only transiently appeared during early influenza
infection will be extremely useful for identifying newly influenza-
infected individuals, which will entitle the opportunity to further
characterize the newly infection and thereby monitor the general
population. Since IgM antibody is the first antibodies elicited in
immune responses following infection, we investigated the kinetics
of IgM antibodies during this 2009 H1N1 influenza prevalence.
Our data showed that among 2009 H1N1 influenza infected
patients ,85% individuals developed IgM antibodies within days
and this number was further increased to .90% if a longitudinal
observation was performed; In contrast, only 6% individuals
showed IgM positive among samples collected from population at
a non-flu season. These data gave rise to a sensitivity at 95% and a
specificity at 82.5%. Since it is known that a sporadic influenza A
virus infection may occasionally occur during non-flu season, the
6% Influenza A IgM positive cases in 2008 non-flu season sera
samples may represent the real newly Influenza A virus infection,
we expected that the specificity for this IgM assay could be above
82.5%. This speculation was further confirmed by the observation
that none positive cases were identified among samples from RSV-
Figure 4. Initial viral load in nasopharyngeal swab and serum IgM affect virus clearance. Proportions of patients with undetectable viral
loads in days since admitted to hospital were graphed with the days post symptom onset. Patients were divided into quartiles by viral load (a) or unit
of IgM (b), 1st and 4th quartiles were showed. Each quartile had 27 subjects; c) The viral loads of patients in groups of 1st and 4th quartiles of IgM
unit were compared.
doi:10.1371/journal.pone.0022603.g004
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influenza season. However, the sensitivity and the specificity of
IgM assay will subject to be further adjusted in a large scale study.
Although previous report in mice model has indicated that
immunoglobulin M antibodies could be induced during influenza
virus infection (3), this report is for the first time to observe that
influenza A specific IgM could appear within days after natural
influenza infection in humans.
The high sensitivity and the good specificity of IgM assay
entitled IgM as a good biomarker for the surveillance of new
influenza infection. IgM ELISA has several advantages over real
time PCR [11,12]. Firstly, ELISA is a test routinely used in clinical
laboratory that doesn’t require specific instruments, therefore, a
regularly clinical laboratory is capable to undertake this detection
task. Secondly, unlike viral load in nasopharyngeal swab which is
quickly declined when medication is taken, IgM response usually
persists for a few days regardless medical intervention. Thirdly, by
the virtue of IgM response it is more important to monitor virus
carriers without obviously symptoms and signs. In addition, the
influenza A specific IgM based assay could remain as an effective
tool for surveillance during circulations of new influenza A
recombinants whereas PCR may miss the detection of the new
recombinants since their primers are non-specific for the new
recombinants. Under this circumstance, IgM assay could be
employed as the first line tool to monitor the surveillance and PCR
plus sequencing could be used thereafter as a tool for genotyping.
Rapid antigen test for Influenza A has been used as a
complementary diagnostic tool in clinical settings, however, this
assay has been generally considered as an assay with low
sensitivity. Indeed, a recent clinical study showed that only
11.1% samples are tested as positive by rapid antigen test in 144
PCR-confirmed positive samples and the paramount feature for
rapid test-positive was high virus concentration (13). In contrast,
85–92% out of 131 PCR-positive samples was positive in IgM
assay in our study, suggesting that IgM assay may represent a
much more sensitive assay than rapid antigen test. In addition,
IgM response lasts longer than viral antigen, therefore, IgM test
could remain as positive in samples which the viral replication
starts to wane and thereby serve as a better complementary
diagnostic tool in clinical settings.
Since previous report demonstrated that IgM responses could
play an important protective role in influenza viral infection in
mice model (3), therefore, we determined whether the higher IgM
level could be associated with quicker viral clearance. Interesting-
ly, our data showed that the group with highest units of IgM
cleared virus fairly quicker than the one with lowest units with the
Figure 5. Time course of HI titers against homologous and heterologous virus strains in week of H1N1 infection. a) HI titers against
2009 H1N1 grouped by days since of illness; b) Longitudinal kinetic of HI titers against 2009 H1N1 in 73 subjects. Paired two samples from each
subject, including one was collected within 3 days after the illness onset and the other was collected during day 4–10, were determined for their HI
titers in parallel and compared; c) HI titers against H3 in 25 paired subjects infected with 2009 H1N1.
doi:10.1371/journal.pone.0022603.g005
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However, a significant difference was only observed in the highest
and lowest IgM groups and the difference was relatively minor, we
concluded that IgM may only play a minor role in natural
influenza viral clearance.
Since the efficacy of this early immune response to clear viruses
is highly relevant to clinical prognosis, we quantified the HI
activities of sera against a primary 2009 H1N1 influenza strain.
Unexpectedly, though we observed that the vast majority of 2009
H1N1 influenza infected individuals developed IgM antibodies
within days after infection and a good influenza A-specific IgM
responses is a prognostic marker for viral clearance, we observed
that nearly all 2009 H1N1 influenza infected individuals have low
or undetectable HI activities in the early days of infection and
good HI activities usually appeared a week after infection; Our
additional experiments demonstrated that HI activities was
conferred by the influenza A-specific IgG antibodies which was
developed later than IgM, these data could explain the delayed
appeared HI activities. Interestingly, we further identified that
early good IgM responses were associated with subsequent good
HI activities which is mediated by influenza A-specific IgG
antibodies, in another word, early good IgM responses is
associated with subsequent good IgG antibody responses,
indicating that there may exist a innate linkage between early
influenza A-specific IgM responses and subsequent IgG antibody
responses, and both may be developed from pre-existing cross-
reactive influenza A-specific immune memory pools in host and
thereby correlated with the early virus clearance. In addition, it is
known that T-cell responses play a role at the early stage of
infection, a complete understanding on the immune responses and
on their association with the viral clearance at the early phase will
need to quantify the Influenza A-specific T cell responses in
combination with humoral responses.
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Figure S2 HI titer in sera of patients cleared the virus is higher
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